Skip to main content

Table 2 Multivariable models of variables associated with endocrine initiation among women tested by Oncotype Dx (N = 1528) and women who were eligible for testing by Oncotype Dx (N = 4674)

From: Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

 

Oncotype Dx-tested

Oncotype Dx-eligible

 

OR

(95% CI)

P

OR

(95% CI)

P

Recurrence score

  

0.02

   

 Low (ref)

      

 Intermediate

0.98

(0.64–1.50)

    

 High

0.40

(0.20–0.81)

    

Tested

     

<0.001

 Yes

   

2.48

(2.03–3.04)

 

 No (ref)

      

Year diagnosed

  

0.13

  

0.004

 2006–2007 (ref)

      

 2008–2009

0.74

(0.49–1.13)

 

0.74

(0.61–0.89)

 

 2010–2012

1.17

0.65–2.09)

 

0.89

(0.70–1.15)

 

Age at diagnosis

  

0.20

  

<0.001

 24–39

0.49

(0.24–1.01)

 

0.59

(0.43–0.82)

 

 40–49

0.73

(0.48–1.11)

 

0.74

(0.60–0.90)

 

 50–59 (ref)

      

 60–63

0.80

(0.49–1.30)

 

1.01

(0.80–1.27)

 

Race-ethnicity

  

0.06

  

0.19

 NH white (ref)

      

 NH black

3.62

(0.83–15.81)

 

0.92

(0.61–1.38)

 

 Hispanic

0.62

(0.27–1.41)

 

0.89

(0.60–1.33)

 

 Other

2.52

(0.89–7.13)

 

1.44

(1.01–2.06)

 

Marital status

  

0.16

  

0.12

Married (ref)

      

Not married

0.76

(0.52–1.11)

 

0.87

(0.72–1.04)

 

Prior cancer

  

0.65

  

0.84

 No (ref)

      

 Yes

1.21

(0.52–2.80)

 

1.04

(0.71–1.53)

 

State

     

0.004

 CA (ref)

      

 GA

0.62

(0.32–1.20)

 

1.15

(0.85–1.55)

 

 KY

1.73

(0.72–4.14)

 

1.71

(1.19–2.47)

 

 NY

1.05

(0.50–2.19)

 

1.60

(1.16–2.20)

 

 OH

1.20

(0.58–2.50)

 

1.45

(1.05–2.00)

 

Area

  

0.74

  

0.70

 Rural (ref)

      

 Urban

1.17

(0.47–2.92)

 

1.08

(0.74–1.56)

 

Median household income

  

0.24

  

0.07

 1 (lowest (ref))

      

 2

1.23

(0.68–2.22)

 

0.96

(0.74–1.26)

 

 3

1.00

(0.57–1.76)

 

0.97

(0.74–1.26)

 

 4

1.84

(0.97–3.49)

 

1.35

(1.02–1.82)

 

 5 (highest)

1.10

0.59–2.07)

 

1.01

(0.75–1.36)

 

Stage

  

0.14

  

0.52

 I (ref)

      

 II

0.71

(0.45–1.12)

 

0.92

(0.71–1.19)

 

Nodal involvement

  

0.22

  

0.10

 N0

0.42

(0.14–1.26)

 

0.87

(0.64–1.17)

 

 N1mic

0.69

(0.18–2.62)

 

1.40

(0.91–2.17)

 

 N1 (ref)

      

HER2 status

  

0.82

  

0.33

 Negative

0.89

(0.49–1.62)

 

1.21

(0.55–2.92)

 

 Borderline

0.63

(0.13–3.06)

 

1.26

(0.94–1.56)

 

 Unknown (ref)

      

Hormone receptor status

     

<0.001

 ER and PR both positive (ref)

      

 Only ER or PR positive

0.80

(0.45–1.42)

 

0.58

(0.47–0.72)

 

Histological grade

  

0.52

  

<0.001

 1–2 (well/moderately differentiated (ref)

      

 3 (poorly or not differentiated)

1.18

(0.71–1.96)

 

0.68

(0.56–0.84)

 

One year comorbidities

  

0.57

  

0.51

 0 (ref)

      

 1 or more

0.86

(0.52–1.43)

 

0.92

(0.72–1.18)

 

Surgery type

  

0.74

  

0.42

 Breast-conserving surgery (ref)

      

 Mastectomy

0.94

(0.47–2.92)

 

0.93

(0.78–1.11)

 

Chemotherapy

  

0.10

   

 No (ref)

      

 Yes

1.49

(0.92–2.39)

    

Chemotherapy

Tested

     

<0.001

 No

Yes

--

  

3.25

(2.53–4.16)

 

No

--

     

 Yes

Yes

--

  

1.35

(0.96–1.90)

 

No

--

     
  1. Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least 2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us